Axogen CEO Karen Zaderej commented, “We are pleased with our Q4 and full-year 2023 performance. Growth in the quarter was driven by improved commercial execution across our products and their applications. As we enter 2024, we continue to fortify our foundation by driving innovation in nerve protection with the planned market expansion for Axoguard HA+TM, the roll-out for Avive+TM, and our BLA submission for Avance, which remains on track for the end of the first half of 2024…”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AXGN:
- Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
- Axogen Announces Promotions on Research and Development Team
- Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
- AxoGen reaffirms FY23 revenue $154M-$159M, consensus $156.75M
- AxoGen appoints Naor as Chief Financial Officer
